17:55 , Oct 6, 2017 |  BC Week In Review  |  Financial News

SpecificiT completes seed financing

On Sept. 11, cancer company SpecificiT Pharma Inc. (Montreal, Quebec) said it completed an undisclosed seed financing in late August led by Sanderling Ventures. Accel-Rx Health Sciences Accelerator and founding investor AmorChem also participated. The...
18:38 , Nov 18, 2016 |  BioCentury  |  Emerging Company Profile

Suppressing somatostatin

Zucara Therapeutics Inc. is developing somatostatin receptor 2 antagonists to prevent hypoglycemia in Type I diabetes patients without decreasing the efficacy of insulin therapy. In Type I diabetes, somatostatin production is elevated, leading to continuous...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Financial News

ScarX completes venture financing

ScarX Therapeutics Inc., Toronto, Ontario   Business: Dermatology   Date completed: 2016-02-16   Type: Venture financing   Raised: C$2 million ($1.4 million)   Investors: Accel-Rx Health Sciences Accelerator; BDC Capital; MaRS Innovation; and other undisclosed investors   ...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Financial News

Encycle Therapeutics completes venture financing

Encycle Therapeutics Inc., Toronto, Ontario   Business: Chemistry, Autoimmune, Cancer   Date completed: 2015-09-30   Type: Venture financing   Raised: C$2.9 million ($2.1 million)   Investors: Takeda Ventures Inc.; Accel-Rx Health Sciences Accelerator; BDC Capital; MaRS Innovation   Note: The...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Accel-Rx Health Sciences Accelerator finance news

Accel-Rx, a pan-Canadian health sciences accelerator, announced its official launch after receiving a C$14.5 million ($13.1 million) award from the Canadian government's Centers of Excellence for Commercialization and Research (CECR) program. CDRD Ventures Inc.,...